📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 14:36
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
26 announcements match the current filters (relevance ≥ 5).
Morepen Lab Q1 Net Profit jumps 570% YoY to ₹54 Cr; Medical Devices hive-off timeline extended
Morepen Laboratories reported a robust Q1 FY27 with consolidated net profit surging to ₹53.99 Cr, compared to ₹8.06 Cr in Q1 FY26. Revenue for the quarter grew 38% YoY to ₹546.35 Cr, significantly exceeding the previous year's quarterly average. The board also approved the re-appointment of Sushil Suri as CMD for three years and extended the timeline for hiving off the Medical Devices business into a subsidiary. A record date of September 19, 2026, has been set for the final dividend.
Confidence: HIGH
What changedSignificant earnings growth and extension of the strategic restructuring timeline for the medical devices segment.
Why it mattersThe earnings jump suggests a potential turnaround or high-margin product mix shift; the hive-off is key to the company's goal of scaling medical devices to 45% of revenue.
Q1 FY27 Net Profit: ₹53.99 CrQ1 FY27 Revenue: ₹546.35 CrYoY Revenue Growth: 38.2%Record Date: September 19, 2026CMD Re-appointment Term: 3 years
📅 Short termThe stock is likely to react positively to the strong YoY and QoQ profit growth.
📈 Long termStructural focus on medical devices and new-generation APIs could re-rate the business if execution remains consistent.
⚠ Risk flags
- Chinese competition in legacy APIs
- Execution of the slump sale
- Related-party transaction complexities
Key Highlights
Consolidated Net Profit for Q1 FY27 rose to ₹53.99 Cr from ₹8.06 Cr in the year-ago period
Total Income increased to ₹546.35 Cr in Q1 FY27, representing a 38% growth over Q1 FY26
Record date for the FY26 final dividend is set for September 19, 2026
CMD Sushil Suri re-appointed for a 3-year term effective October 20, 2026
Timeline extended for the slump sale of the Medical Devices business to Morepen Medipath Limited
👀 What to Watch
Watch for the completion of the Medical Devices hive-off and whether the Q1 margin improvement is sustainable against Chinese API pricing pressure.
Morepen Labs Q1 Net Profit Jumps 570% YoY to ₹54 Cr; CMD Re-appointed for 3 Years
Morepen Laboratories reported a robust performance for Q1 FY27, with consolidated net profit surging to ₹53.99 Cr from ₹8.06 Cr in the year-ago period. Total revenue grew 38% YoY to ₹546.35 Cr, driven by strong operational performance. The board has approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a three-year term starting October 2026. Additionally, the company set September 19, 2026, as the record date for the FY26 final dividend and extended the timeline for hiving off its Medical Devices business.
Confidence: HIGH
What changedThe company delivered a significant earnings beat for Q1 FY27 and secured leadership continuity by re-appointing its promoter-CMD for another three years.
Why it mattersThe sharp profit growth suggests improved margins or a better product mix, while the restructuring of the Medical Devices unit is a strategic move to scale a segment that aims to contribute 45% of total revenue.
Q1 FY27 Net Profit: ₹53.99 CrYoY Profit Growth: 569.8%Q1 FY27 Revenue: ₹546.35 CrDividend Record Date: September 19, 2026CMD Re-appointment Term: 3 Years
📅 Short termThe stock is likely to react positively in the short term due to the substantial YoY and QoQ growth in profitability and revenue.
📈 Long termThe long-term outlook depends on the successful hive-off of the Medical Devices business and the company's ability to transition from legacy APIs to high-margin new-generation products.
⚠ Risk flags
- Intense pricing competition from Chinese API manufacturers
- Execution risk regarding the slump sale of the Medical Devices business
- High dependency on legacy API realizations
Key Highlights
Consolidated Net Profit increased by 569.8% YoY to ₹53.99 Cr in Q1 FY27
Total Revenue from operations rose 38.1% YoY to ₹546.35 Cr compared to ₹395.38 Cr
Mr. Sushil Suri re-appointed as CMD for a 3-year term effective from October 20, 2026
Record date for final dividend (FY26) fixed as September 19, 2026
Timeline extended for the slump sale of the Medical Devices business into Morepen Medipath Limited
👀 What to Watch
Investors should monitor the upcoming 41st AGM on September 26, 2026, for shareholder approval of the CMD re-appointment and the Medical Devices business restructuring.
Morepen Lab Q1 Net Profit Jumps 569% to ₹53.99 Cr; Dividend Record Date Set for Sept 19
Morepen Laboratories reported a robust Q1 FY27 with consolidated net profit surging to ₹53.99 Cr, a 569% increase from ₹8.06 Cr in the year-ago period. The Board has fixed September 19, 2026, as the record date for the final dividend of FY26, pending shareholder approval. Additionally, the company extended the timeline for hiving off its Medical Devices business into a subsidiary, Morepen Medipath Limited, to streamline operations. Chairman & Managing Director Sushil Suri has been re-appointed for a further three-year term effective October 2026.
Confidence: HIGH
What changedThe company reported a massive quarterly earnings beat and formalized the timeline for its dividend payout and leadership continuity.
Why it mattersThe sharp increase in profitability (Q1 profit is ~56% of the entire previous TTM PAT) indicates a potential structural shift in margins or product mix. The restructuring of the Medical Devices segment is critical for valuation unlocking as it is a high-growth focus area.
Q1 FY27 Net Profit: ₹53.99 CrQ1 FY26 Net Profit: ₹8.06 CrQ1 Profit vs TTM PAT: 56.2%Dividend Record Date: 19-Sep-2026CMD Re-appointment Term: 3 years
📅 Short termThe stock is likely to react positively to the substantial earnings growth and the clarity provided on the dividend record date.
📈 Long termThe long-term trajectory depends on the successful scaling of the Medical Devices segment and the transition to new-generation APIs to counter Chinese pricing pressure.
⚠ Risk flags
- High dependency on legacy APIs vulnerable to Chinese competition
- Execution risk in the slump sale of the Medical Devices business
- Regulatory risks associated with USFDA/EU-GMP inspections
Key Highlights
Consolidated Net Profit for Q1 FY27 reached ₹53.99 Cr, significantly exceeding the ₹8.06 Cr reported in Q1 FY26.
Profit Before Tax (PBT) for the quarter stood at ₹72.15 Cr compared to ₹11.35 Cr in the corresponding previous quarter.
Record date for the final dividend is confirmed as September 19, 2026, with the AGM scheduled for September 26, 2026.
Re-appointment of Mr. Sushil Suri as CMD approved for a 3-year tenure from October 20, 2026, to October 19, 2029.
Extension granted for the slump sale of the Medical Devices business, which the company aims to scale to 45% of total revenue.
👀 What to Watch
Investors should monitor the execution of the Medical Devices business hive-off and the margin sustainability in the API segment given the 569% profit jump. Watch for the 41st AGM outcomes on September 26 for final dividend approval.
394% PAT Growth: Morepen Labs reports record Q1 FY27 revenue and CDMO commercialization
Morepen Laboratories reported its highest-ever quarterly performance in Q1 FY27, with revenue growing 34% YoY to Rs 575.31 Cr. Profitability saw a massive surge, with PAT increasing 394% YoY to Rs 56.35 Cr and EBITDA margins expanding significantly to 15.25% from 6.65% YoY. A major strategic milestone was reached as the company's Rs 825 Cr CDMO mandate entered full-scale commercialization, contributing Rs 58 Cr in dispatches during the quarter. The company also maintained a clean regulatory record with its fourth consecutive USFDA inspection resulting in zero observations.
Confidence: HIGH
What changedMorepen has successfully transitioned from a transaction-led API business to a commercial-scale CDMO player, evidenced by the first major dispatches under its Rs 825 Cr mandate.
Why it mattersThe significant margin expansion (from 6.65% to 15.25%) indicates a structural shift toward higher-value products and better operating leverage, potentially re-rating the company's historical low-margin profile.
Q1 FY27 Revenue: Rs 575.31 CrPAT Growth (YoY): 394%CDMO Mandate Value: Rs 825 CrCDMO Mandate vs TTM Revenue: ~45.7%EBITDA Margin: 15.25%Target Capacity (FY30): 1,200 KL
📅 Short termThe stock is likely to react positively to the record earnings and the successful start of the CDMO commercialization phase.
📈 Long termThe shift toward long-duration CDMO partnerships and innovation-led manufacturing could lead to more predictable and higher-margin earnings over the next 3-4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the large CDMO mandate
- Vulnerability to input cost fluctuations in the API segment
- Concentration of manufacturing at the Baddi complex
Key Highlights
Quarterly PAT surged 394% YoY to Rs 56.35 Cr, which is approximately 58% of the total PAT recorded in the entire previous fiscal year (FY26).
Revenue reached a record Rs 575.31 Cr, driven by a 111% growth in export revenue and a 31% growth in the API segment.
EBITDA grew by 207% YoY to Rs 87.72 Cr, with margins improving by 860 basis points to 15.25%.
The Rs 825 Cr CDMO mandate has commenced commercialization, with Rs 58 Cr worth of supplies completed in Q1 FY27.
API exports grew 42% YoY, while the Medical Devices segment continued to scale with 19% growth.
👀 What to Watch
Investors should monitor the quarterly execution rate of the remaining ~Rs 767 Cr CDMO mandate and the progress of the phased capacity expansion to 1,200 KL by FY30.
Rs 575 Cr Revenue & 394% PAT Growth: Morepen Labs Q1 FY27 Performance
Morepen Laboratories reported a strong Q1 FY27 with revenue growing 34% YoY to Rs 575.31 Cr. The company achieved significant margin expansion, with EBITDA rising 207% to Rs 87.72 Cr and PAT surging 394% to Rs 56.35 Cr. This performance was driven by the commercialization of a large Rs 825 Cr CDMO mandate, which contributed Rs 58 Cr in dispatches this quarter. Additionally, the company is executing a major capacity expansion, aiming to double its API capacity from 600 KL to 1200 KL by FY30.
Confidence: HIGH
What changedMorepen has successfully transitioned from a commodity-focused API player to a higher-margin CDMO and medical devices platform, as evidenced by the 3x jump in EBITDA.
Why it mattersThe shift toward long-duration CDMO programs and recurring medical device consumables (500 Mn strips/annum) provides more predictable and higher-quality earnings compared to volatile legacy APIs.
Q1 FY27 Revenue: Rs 575.31 CrPAT Growth (YoY): 394%CDMO Mandate Value: Rs 825 CrCDMO Mandate vs TTM Revenue: ~45.7%Target API Capacity (FY30): 1200 KLEBITDA Margin: 15.25%
📅 Short termThe stock is likely to react positively to the sharp earnings beat and the successful commercial validation of the CDMO strategy.
📈 Long termThe doubling of API capacity and the focus on complex chemistry and medical device consumables could structurally re-rate the business over the next 3-4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in doubling manufacturing capacity
- Pricing pressure in legacy API segments
- Regulatory compliance for global exports
Key Highlights
Quarterly revenue reached a record Rs 575.31 Cr, representing a 34% YoY growth.
PAT increased by 394% YoY to Rs 56.35 Cr, driven by operating leverage and a better product mix.
EBITDA margins expanded significantly to 15.25% from 6.65% in the previous year's quarter.
Commenced commercial supplies for a Rs 825 Cr CDMO mandate, with Rs 58 Cr dispatched in Q1.
API capacity expansion roadmap targets an increase from 600 KL to 1200 KL by FY30, with Phase-1 (1000 KL) expected by Q4 FY26.
👀 What to Watch
Investors should monitor the ramp-up of the remaining Rs 767 Cr CDMO mandate and the timely completion of the Phase-1 capacity expansion to 1000 KL by Q4 FY26.
Morepen Lab Q1 Net Profit Jumps 570% YoY to ₹53.99 Cr; Medical Device Hive-off Timeline Extended
Morepen Laboratories reported a robust Q1 FY27 with consolidated net profit surging to ₹53.99 Cr from ₹8.06 Cr in the same quarter last year. Total revenue for the quarter grew 38.2% YoY to ₹546.35 Cr, significantly outpacing the previous year's performance. The board has set September 19, 2026, as the record date for the final dividend and extended the timeline for hiving off its medical devices business into a subsidiary. Additionally, Chairman Sushil Suri has been re-appointed for a three-year term starting October 2026.
Confidence: HIGH
What changedThe company delivered a massive earnings beat compared to the previous year and provided a concrete record date for dividends while extending the strategic restructuring of its medical devices division.
Why it mattersThe significant jump in profitability (EPS up from ₹0.15 to ₹0.99) suggests a major shift in operational efficiency or product mix. The hive-off of the medical devices business is a key step toward potentially unlocking value in that high-growth segment.
Q1 FY27 Net Profit: ₹53.99 CrQ1 FY27 Revenue: ₹546.35 CrQ1 Revenue vs TTM Revenue: ~30.2%YoY Profit Growth: 569.8%Dividend Record Date: 19th September 2026
📅 Short termThe stock is likely to react positively to the substantial YoY growth in both revenue and net profit, which far exceeds recent quarterly averages.
📈 Long termThe structural hiving off of the medical devices business into a separate subsidiary could lead to a future value-unlocking event (like an IPO or strategic stake sale), while the re-appointment of the CMD ensures leadership continuity.
⚠ Risk flags
- Related-party transaction risk regarding the slump sale to a subsidiary
- High dependency on legacy API pricing which remains volatile
Key Highlights
Consolidated Net Profit increased by 569.8% YoY to ₹53.99 Cr in Q1 FY27
Total Income for the quarter rose 38.2% to ₹546.35 Cr compared to ₹395.38 Cr in Q1 FY26
Basic EPS improved significantly to ₹0.99 from ₹0.15 in the year-ago period
Record date for final dividend (FY26) confirmed as September 19, 2026
Timeline extended for hiving off the Medical Devices Business into Morepen Medipath Limited via slump sale
👀 What to Watch
Investors should monitor the upcoming 41st AGM on September 26, 2026, for formal approval of the medical device business restructuring and the re-appointment of the CMD. The sharp margin improvement in Q1 warrants a close look at the sustainability of product realizations in the API segment.
₹825 Cr CDMO Mandate: Morepen Starts Commercial Supplies with ₹50 Cr Q1 Dispatch
Morepen Laboratories has transitioned its ₹825 crore CDMO mandate from the validation phase to commercial execution, marking a significant scale-up in its business model. The company completed its first dispatch of ₹50 crore in Q1 FY2026-27 and has guided for a substantial ramp-up to ₹225 crore in Q2 FY2026-27. This single mandate represents approximately 45.7% of the company's TTM revenue of ₹1,806 crore, providing high revenue visibility. To support this growth, the company is expanding reactor capacity from a target of 600 KL in Q2 to 1,000 KL in subsequent phases.
Confidence: HIGH
What changedMorepen has moved from the preparation/validation stage to the revenue-generation stage for its largest-ever CDMO contract.
Why it mattersThe mandate is massive relative to the company's current size (~46% of annual revenue) and signals a strategic shift away from price-sensitive legacy APIs toward stable, long-term contract manufacturing.
CDMO Mandate Value: ₹825 CrMandate vs TTM Revenue: 45.7%Q1 FY27 Dispatch: ₹50 CrQ2 FY27 Expected Supply: ₹225 CrUltimate Reactor Capacity: 1,000 KL
📅 Short termThe stock is likely to react positively to the clear revenue guidance for Q2 and the successful start of commercial supplies, which de-risks the project execution.
📈 Long termIf executed successfully, this mandate could structurally improve Morepen's margin profile and reduce its vulnerability to Chinese API pricing competition.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in scaling capacity to 1,000 KL
- High customer concentration for this specific mandate
- Regulatory compliance requirements for global supplies
Key Highlights
Commenced commercial execution of a ₹825 crore long-term CDMO mandate
Completed first commercial dispatch valued at ₹50 crore during Q1 FY2026-27
Projected supply ramp-up to ₹225 crore for Q2 FY2026-27, subject to schedules
Phased expansion of reactor capacity from 600 KL to 1,000 KL to support the mandate
Transitioned from low-margin legacy API focus toward high-value global manufacturing partnerships
👀 What to Watch
Watch for the successful delivery of the ₹225 crore Q2 target and the subsequent impact on operating margins, which stood at a modest 6.9% TTM. Investors should also track the timeline for the 1,000 KL capacity expansion.
Morepen Labs Elevates Sanjay Suri to Managing Director Effective July 1, 2026
Morepen Laboratories has approved the elevation of Mr. Sanjay Suri from Whole-time Director to Managing Director, effective July 1, 2026. He will jointly oversee the company's management and operations alongside the current Chairman & MD, Mr. Sushil Suri, for a tenure lasting until August 12, 2028. Mr. Sanjay Suri is a member of the promoter group and brings over 30 years of experience in international sales, manufacturing, and USFDA regulatory approvals. This move formalizes a dual-leadership structure for the company, which reported a TTM revenue of Rs 1,806 Cr.
Confidence: HIGH
What changedMr. Sanjay Suri's designation has been upgraded from Whole-time Director to Managing Director, granting him joint oversight of the company's operations.
Why it mattersThe move ensures leadership continuity within the promoter family and potentially streamlines decision-making as the company pursues growth in new-generation APIs and global markets.
Tenure End Date: August 12, 2028Experience: 30+ yearsTTM Revenue: Rs 1806 CrMarket Cap: Rs 3256 Cr
📅 Short termThe market is likely to view this as a routine internal promotion within the promoter group, with minimal immediate impact on the stock price.
📈 Long termProvides leadership stability for the company's long-term strategy of diversifying into medical devices and high-margin APIs.
⚠ Risk flags
- Related-party leadership (both MDs are brothers and promoters)
Key Highlights
Elevation of Mr. Sanjay Suri to Managing Director effective July 1, 2026
Tenure set for the balance of his existing term until August 12, 2028
Mr. Sanjay Suri possesses over 30 years of experience in the pharmaceutical industry
Joint management structure established with Chairman & MD Mr. Sushil Suri
Appointment is subject to shareholder approval within prescribed statutory timelines
👀 What to Watch
Monitor for any shifts in strategic execution or operational efficiency as the company defines specific roles for the two Managing Directors, particularly in the scaling of the medical devices segment.
Morepen Labs Q4 Revenue Up 22% to Rs 472 Cr; Secures Rs 823 Cr CDMO Mandate
Morepen Laboratories reported a strong performance for Q4 FY26, with revenue growing 22% YoY to Rs. 472 crore, led by a 31% jump in Medical Devices and 17% in APIs. The company has secured a significant multi-year CDMO mandate worth Rs. 823 crore, with commercial production already commenced. A strategic shift is underway to move from transaction-led sales to long-duration programs, aiming to expand EBITDA margins from 10-11% to over 20%. Capacity expansion is also planned, targeting an increase from 500 KL to 1,000 KL in the long term.
Key Highlights
Q4 FY26 revenue grew 22% YoY to Rs. 472 Cr, while full-year FY26 growth stood at 8%
Secured a major multi-year CDMO mandate worth Rs. 823 Cr with phased delivery starting shortly
Capacity expansion roadmap from current ~500 KL to ~800 KL (mid-term) and ~1000 KL (long-term)
Targeting a significant EBITDA margin expansion from 10-11% to a 20%+ profile
Maintained regulatory excellence with 4th consecutive USFDA inspection resulting in NIL 483 observations
👀 What to Watch
Investors should focus on the company's execution of the Rs. 823 Cr CDMO order and the timeline for capacity expansion as these are critical for achieving the 20% margin target. The transition toward a more stable, recurring revenue model makes it a strong candidate for long-term monitoring in the pharma and diagnostics space.
Morepen Labs Q4 Net Profit Jumps 69% to Rs 20 Cr; Proposes 10% Dividend
Morepen Laboratories reported a strong 69% YoY growth in Q4 FY26 net profit to Rs. 20 crore, driven by a 22% increase in revenue to Rs. 472 crore. The company has successfully transitioned its CDMO program into commercial execution following a major $91 million global mandate. While EBITDA remained flat at Rs. 32 crore due to heavy growth investments, the Medical Devices segment showed robust growth of 31%. The board has proposed a 10% dividend, reflecting confidence in the long-term shift towards a manufacturing-led platform.
Key Highlights
Q4 Net Profit surged 69% YoY to Rs. 20 crore on revenue of Rs. 472 crore (up 22%)
Commenced commercial production for a multi-year Rs. 825 crore ($91M) global CDMO mandate
Medical Devices business grew 31% in Q4, reaching an annual revenue of Rs. 598 crore
Manufacturing capacity expansion underway from 500 KL to 800 KL, with a long-term goal of 1000 KL
Successfully completed 4th consecutive USFDA inspection with zero 483 observations
👀 What to Watch
Investors should view the transition from a traditional API model to a high-margin CDMO and Medical Devices platform as a long-term value driver. Monitor the execution of the $91M mandate and the impact of capacity expansion on future margins.
Morepen Labs Recommends ₹0.20 Dividend and Updates Medical Devices Business Hive-off
Morepen Laboratories has recommended a final dividend of ₹0.20 per equity share (10% of face value) for FY 2025-26. The company has also revised the 'Appointed Date' for hiving off its Medical Devices business to Morepen Medipath Limited to April 1, 2026, due to regulatory delays. Notably, Dr. Morepen Limited ceased to be a subsidiary during the year after the company's stake was reduced from 80% to 19.94%. The board has approved audited FY26 results with an unmodified auditor opinion, signaling financial transparency.
Key Highlights
Recommended a final dividend of ₹0.20 per equity share of face value ₹2 for FY 2025-26.
Revised the 'Appointed Date' for the Medical Devices business slump sale to April 1, 2026.
Dr. Morepen Limited ceased to be a subsidiary effective July 31, 2025, following a stake reduction to 19.94%.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Re-appointed M/s. Vijender Sharma & Co. as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors should track the completion of the Medical Devices business transfer to the subsidiary, which is a key strategic move for the company. The dividend recommendation reflects stable cash flows, but the primary focus should remain on the impact of the restructuring on future margins.
Morepen Labs Approves FY26 Results, Recommends ₹0.20 Dividend & Updates Medical Business Sale
Morepen Laboratories has announced its audited financial results for the fiscal year ended March 31, 2026, alongside a final dividend recommendation of ₹0.20 per share. The company also approved a second addendum to the Business Transfer Agreement for its Medical Devices Business, shifting the 'Appointed Date' to April 1, 2026, due to regulatory delays. This slump sale to its subsidiary, Morepen Medipath Limited, will be valued based on March 31, 2026, financial statements. Furthermore, the company noted the deconsolidation of Dr. Morepen Limited following a stake reduction to 19.94% earlier in the fiscal year.
Key Highlights
Recommended a final dividend of ₹0.20 per equity share of face value ₹2 for FY 2025-26.
Approved the audited financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion.
Extended the 'Appointed Date' for the Medical Devices Business slump sale to April 1, 2026, pending regulatory approvals.
Confirmed the reduction of shareholding in Dr. Morepen Limited from 80% to 19.94% effective July 31, 2025.
Re-appointed M/s. Vijender Sharma & Co. as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors should note the dividend payout and the strategic hiving off of the Medical Devices segment, which aims to streamline operations. Monitor the final valuation of the slump sale as it will be determined by the FY26 financial statements.
Morepen Labs Recommends ₹0.20 Final Dividend and Updates Medical Devices Hive-off Plan
Morepen Laboratories has recommended a final dividend of ₹0.20 per equity share (10% of face value) for the financial year ended March 31, 2026. The company also approved a second addendum to its Business Transfer Agreement to hive off its Medical Devices business to subsidiary Morepen Medipath on a slump sale basis, with a revised appointed date of April 1, 2026. During the fiscal year, the group structure saw a significant change as Dr. Morepen Limited ceased to be a subsidiary following a stake reduction from 80% to 19.94%. The board has also approved the audited financial results for FY26 with an unmodified audit opinion.
Key Highlights
Recommended a final dividend of ₹0.20 per equity share of face value ₹2 each for FY26
Revised the 'Appointed Date' for the hive-off of the Medical Devices business to April 1, 2026
The Medical Devices business transfer to Morepen Medipath (51% subsidiary) will be executed on a slump sale basis
Dr. Morepen Limited ceased to be a subsidiary effective July 31, 2025, following a stake dilution to 19.94%
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY26
👀 What to Watch
Investors should track the progress of the Medical Devices business hive-off as it may lead to better value unlocking for the core pharmaceutical business. The dividend provides a modest yield, but the strategic restructuring of subsidiaries remains the primary long-term monitorable.
Morepen Labs Approves ₹0.20 Dividend and Revises Medical Devices Business Hive-off Date
Morepen Laboratories has recommended a final dividend of ₹0.20 per equity share for the financial year ended March 31, 2026. The Board also approved a second addendum to the Business Transfer Agreement (BTA) for hiving off its Medical Devices business to its 51% subsidiary, Morepen Medipath Limited, on a slump sale basis. The 'Appointed Date' for this transfer has been revised to April 1, 2026, due to delays in obtaining regulatory approvals. Additionally, the company confirmed that Dr. Morepen Limited ceased to be a subsidiary during the year following a stake reduction to 19.94%.
Key Highlights
Recommended a final dividend of ₹0.20 per equity share of face value ₹2 each for FY26.
Revised the 'Appointed Date' for the Medical Devices business slump sale to April 1, 2026.
The slump sale valuation will be determined based on the financial statement of the undertaking as of March 31, 2026.
Dr. Morepen Limited ceased to be a subsidiary effective July 31, 2025, after shareholding dropped from 80% to 19.94%.
Statutory auditors issued an unmodified opinion on the audited standalone and consolidated financial results for FY26.
👀 What to Watch
Investors should note the dividend payout and the strategic restructuring of the Medical Devices business into a separate subsidiary. Monitor the completion of the slump sale by the new April 2026 deadline for potential value unlocking.
Morepen Labs Reduces Stake in Subsidiary MML to 51% via Share Transfer to Business Head
Morepen Laboratories has approved the transfer of 1,62,000 equity shares of its subsidiary, Morepen Medipath Limited (MML), to Mr. Anubhav Suri, the Head of the Medical Device Business. This transaction reduces the parent company's stake in MML from 60% to 51%, while Mr. Suri's personal stake increases from 0.10% to 9.10%. The move is designed to reward long-term leadership and align executive interests with the growth of the medical devices segment. MML will continue to be a subsidiary and its financials will remain consolidated with Morepen Laboratories.
Key Highlights
Transfer of 1,62,000 equity shares of Morepen Medipath Limited (MML) to the business head.
Morepen Laboratories' shareholding in the subsidiary reduced from 60% to 51%.
Mr. Anubhav Suri's stake in MML increased significantly from 0.10% to 9.10%.
MML remains a subsidiary and will continue to be consolidated in financial statements.
The restructuring aims to ensure leadership continuity in the high-growth medical devices vertical.
👀 What to Watch
Investors should view this as a talent retention and incentive alignment move for a key business vertical. No immediate action is required as the company maintains majority control and consolidation of the subsidiary.
Morepen Labs Secures ₹30 Crore Unsecured Term Loan from Shinhan Bank at 7.60% Interest
Morepen Laboratories has executed a loan agreement with Shinhan Bank to avail an unsecured term loan of ₹30 crore for general business purposes. The facility carries a competitive interest rate of 7.60% per annum with a 36-month tenure and a 6-month moratorium. This loan is backed by a personal guarantee from the Promoter and CMD, Mr. Sushil Suri. The company's existing debt exposure stands at ₹182.62 crore, of which ₹20.45 crore is already with Shinhan Bank.
Key Highlights
Approved an unsecured term loan of ₹30 crore from Shinhan Bank for general business purposes.
Interest rate is 7.60% (Repo + 2.35% spread) with a 36-month tenure and 6-month moratorium.
Total existing debt exposure stands at ₹182.62 crore, excluding vehicle loans.
The loan is supported by a personal guarantee from Promoter and CMD Mr. Sushil Suri.
Repayment will be made in 10 equal quarterly installments following the moratorium.
👀 What to Watch
The loan amount is relatively small compared to the company's total debt, but the competitive interest rate and unsecured nature are positive indicators of creditworthiness. Investors should monitor the company's debt-to-equity ratio as it continues to fund general operations through debt.
Morepen Lab Secures 4th Consecutive Zero-Observation USFDA Inspection at Masulkhana Facility
Morepen Laboratories has successfully cleared a USFDA inspection at its Masulkhana, Himachal Pradesh API manufacturing facility with zero observations (NIL Form 483). This marks the company's fourth consecutive clean inspection over the last eight years, highlighting a robust culture of regulatory compliance. The successful audit is expected to pave the way for long-term supply contracts in highly regulated markets like the US and Europe. Morepen, which currently exports to over 80 countries, is also leveraging this track record to strategically expand into the high-margin CDMO space.
Key Highlights
Successful completion of USFDA inspection at Masulkhana facility with Zero observations (NIL Form 483).
Achievement represents the 4th consecutive NIL 483 inspection for Morepen over the past 8 years.
Company maintains market leadership in 6 key APIs and exports to more than 80 countries globally.
Strategic pivot toward the CDMO sector is underway to leverage regulatory excellence and infrastructure.
Investments in digital systems and automation have ensured full compliance with current ICH and CFR guidelines.
👀 What to Watch
This regulatory milestone significantly de-risks Morepen's US export business and enhances its credibility for the upcoming CDMO expansion. Investors should view this as a strong fundamental indicator and monitor for new high-value contract wins in the API and CDMO segments.
Morepen Laboratories Repays ₹99 Crore Credit Facility to Kotak Mahindra Bank
Morepen Laboratories has successfully repaid its entire credit facility totaling ₹99 crore to Kotak Mahindra Bank. The facility consisted of a ₹79 crore working capital demand loan and a ₹20 crore cash credit limit. The repayment was effective as of March 2, 2026, and the bank is now in the process of releasing the assets previously held as security. This move signifies improved liquidity and a commitment to deleveraging the balance sheet.
Key Highlights
Full repayment of ₹99 crore credit facility to Kotak Mahindra Bank completed
Facility included ₹79 crore working capital demand loan and ₹20 crore cash credit
Repayment effective from March 2, 2026, with No Dues Certificate in process
Release of charged assets will improve the company's financial flexibility
👀 What to Watch
This is a positive development indicating strong internal accruals and debt reduction. Investors should look for a reduction in interest expenses in the upcoming quarterly financial statements.
Morepen Labs Secures ₹30 Crore Unsecured Working Capital Loan from KEB Hana Bank
Morepen Laboratories has entered into an agreement with KEB Hana Bank to avail an unsecured working capital term loan of ₹30 crore. The loan carries a competitive interest rate of 7.30% per annum (Repo + 2.05%) and has a tenure of 3 years, including a 6-month moratorium. This facility is backed by a personal guarantee from the Promoter and CMD, Mr. Sushil Suri. The company's existing debt, excluding this new facility, stands at ₹164.62 crore.
Key Highlights
Execution of a ₹30 crore unsecured working capital term loan facility with KEB Hana Bank.
Interest rate set at prevailing repo rate + 2.05%, currently effective at 7.30% per annum.
Loan tenure of 3 years with a 6-month moratorium and 5 half-yearly equal installments.
Personal guarantee provided by Promoter, Chairman & Managing Director Mr. Sushil Suri.
Total outstanding debt of the company (excluding this loan) is ₹164.62 crore as of March 10, 2026.
👀 What to Watch
Investors should monitor the company's debt-to-equity ratio and ensure that the additional working capital effectively supports revenue growth. The promoter's personal guarantee is a positive sign of internal confidence in the company's repayment capacity.
Morepen Labs Bags ₹825 Crore Global CDMO Order from International Pharma Major
Morepen Laboratories has secured a significant international commercial supply contract worth approximately ₹825 crore (USD 91 million) from a leading global pharmaceutical company. This deal marks a major strategic expansion into the high-growth CDMO segment, with supplies expected to commence within the next 4-5 months. The contract is scheduled for execution over a 12-15 month period, concluding by Q1 of the following fiscal year. This order represents a substantial revenue opportunity and a shift towards higher-margin manufacturing services.
Key Highlights
Secured a ₹825 crore (USD 91 million) international CDMO contract from a global pharma major
Execution timeline set for 12-15 months with supplies starting in 4-5 months
Strategic entry into the high-margin Contract Development and Manufacturing Organization (CDMO) segment
Contract includes both development and manufacturing services for the international market
👀 What to Watch
Investors should view this as a major growth catalyst that significantly improves revenue visibility and potential margins. Monitor the commencement of supplies in the next two quarters to ensure execution remains on track.
